American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Recent drug approvals for newly diagnosed acute myeloid leukemia: gifts or a Trojan horse?

(2020) Elihu Estey et al.   LEUKEMIA

Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients—a real-world experience from India

(2019) Govind B. Kanakasetty et al.   ANNALS OF HEMATOLOGY

Function, Survival, and Care Utilization Among Older Adults With Hematologic Malignancies

(2019) Clark DuMontier et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Gait speed, grip strength, and clinical outcomes in older patients with hematologic malignancies

(2019) Michael A. Liu et al.   BLOOD

Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia

(2018) Thomas W. LeBlanc et al.   BLOOD

Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience

(2018) Bolanle Gbadamosi et al.   Clinical Lymphoma Myeloma & Leukemia

Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia

(2018) Laura C. Michaelis et al.   EXPERT OPINION ON PHARMACOTHERAPY

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged ≥ 75 years

(2018) Victoria V. Prassek et al.   HAEMATOLOGICA

Social preferences for health states associated with acute myeloid leukemia for patients undergoing treatment in the United Kingdom

(2018) Nacho Castejón et al.   Health and Quality of Life Outcomes

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged ≥ 75 years

(2018) Victoria V. Prassek et al.   HAEMATOLOGICA

Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers

(2018) Tammy T. Hshieh et al.   JAMA Oncology

Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States

(2018) Eytan M. Stein et al.   Health and Quality of Life Outcomes

Health State Utilities for Acute Myeloid Leukaemia: A Time Trade-off Study

(2018) Namita Joshi et al.   PHARMACOECONOMICS

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

(2018) Jorge E. Cortes et al.   LEUKEMIA

Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience

(2018) Pankit Vachhani et al.   LEUKEMIA RESEARCH

Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial

(2018) Nicholas J Short et al.   Lancet Haematology

Prospective randomization of post-remission therapy comparing autologous peripheral blood stem cell transplantation versus high-dose cytarabine consolidation for acute myelogenous leukemia in first remission

(2017) Toshihiro Miyamoto et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study

(2017) Antonio Almeida et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

GRADE Evidence to Decision (EtD) frameworks for adoption, adaptation, and de novo development of trustworthy recommendations: GRADE-ADOLOPMENT

(2017) Holger J. Schünemann et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Effects of Education and Income on Treatment and Outcome in Patients With Acute Myeloid Leukemia in a Tax-Supported Health Care System: A National Population-Based Cohort Study

(2017) Lene Sofie Granfeldt Østgård et al.   JOURNAL OF CLINICAL ONCOLOGY

Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years

(2017) Alexander D. Heini et al.   LEUKEMIA RESEARCH

Red blood cell transfusion in adult palliative care: a systematic review

(2017) Nicolas Chin-Yee et al.   TRANSFUSION

Azacitidine or intensive chemotherapy for older patients with secondary or therapy-related acute myeloid leukemia

(2017) Pierre-Yves Dumas et al.   Oncotarget

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality

(2017) Mohamed L. Sorror et al.   JAMA Oncology

Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis

(2016) Armin Rashidi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Intensity of end-of-life care for patients with myelodysplastic syndromes: Findings from a large national database

(2016) Sean A. Fletcher et al.   CANCER

Comparison of Reduced-Intensity Idarubicin and Daunorubicin Plus Cytarabine as Induction Chemotherapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia

(2016) Hui Liu et al.   CLINICAL DRUG INVESTIGATION

An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed With Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records From US Community Oncology Practices

(2016) Esprit Ma et al.   Clinical Lymphoma Myeloma & Leukemia

Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients

(2016) Koichi Takahashi et al.   Clinical Lymphoma Myeloma & Leukemia

GRADE Guidelines: 16. GRADE evidence to decision frameworks for tests in clinical practice and public health

(2016) Holger J. Schünemann et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial

(2016) Sergio Amadori et al.   JOURNAL OF CLINICAL ONCOLOGY

A clinical trial for patients with acute myeloid leukemia or myelodysplastic syndromes not eligible for standard clinical trials

(2016) G Montalban-Bravo et al.   LEUKEMIA

Treatment patterns and comparative effectiveness in elderly acute myeloid leukemia patients (age 70 years or older): the Lyon-university hospital experience

(2016) Maël Heiblig et al.   LEUKEMIA & LYMPHOMA

The outcome and prognostic factors of 248 elderly patients with acute myeloid leukemia treated with standard-dose or low-intensity induction therapy

(2016) Yi Chen et al.   MEDICINE

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2016) John S. Welch et al.   NEW ENGLAND JOURNAL OF MEDICINE

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

(2016) Pablo Alonso-Coello et al.   BMJ-British Medical Journal

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction

(2016) Pablo Alonso-Coello et al.   BMJ-British Medical Journal

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines

(2016) Pablo Alonso-Coello et al.   BMJ-British Medical Journal

GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction

(2016) Pablo Alonso-Coello et al.   BMJ-British Medical Journal

Fitness in the elderly: how to make decisions regarding acute myeloid leukemia induction

(2016) A. V. Rao   Hematology-American Society of Hematology Education Program

High-Intensity Induction Chemotherapy Is Feasible for Elderly Patients with Acute Myeloid Leukemia

(2015) Adi Shacham-Abulafia et al.   ACTA HAEMATOLOGICA

Selection of Elderly Acute Myeloid Leukemia Patients for Intensive Chemotherapy: Effectiveness of Intensive Chemotherapy and Subgroup Analysis

(2015) Dae Sik Kim et al.   ACTA HAEMATOLOGICA

Characterization and prognostic features of secondary acute myeloid leukemia in a population-based setting: A report from the Swedish Acute Leukemia Registry

(2015) Erik Hulegårdh et al.   AMERICAN JOURNAL OF HEMATOLOGY

Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States

(2015) Bruno C. Medeiros et al.   ANNALS OF HEMATOLOGY

Decitabine versus best supportive care in older patients with refractory anemia with excess blasts in transformation (RAEBt) - results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group (GMDSSG)

(2015) Heiko Becker et al.   ANNALS OF HEMATOLOGY

Guidelines International Network: Principles for Disclosure of Interests and Management of Conflicts in Guidelines

(2015) Holger J. Schünemann et al.   ANNALS OF INTERNAL MEDICINE

Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia

(2015) M. Dennis et al.   BLOOD

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Health care utilization and end-of-life care for older patients with acute myeloid leukemia

(2015) Areej R. El-Jawahri et al.   CANCER

Effect of Age on Treatment Decision-Making in Elderly Patients With Acute Myeloid Leukemia

(2015) Jihane Fattoum et al.   Clinical Lymphoma Myeloma & Leukemia

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO)

(2015) C. Kahl et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Prognostic Significance ofNPM1Mutations in the Absence ofFLT3–Internal Tandem Duplication in Older Patients With Acute Myeloid Leukemia: A SWOG and UK National Cancer Research Institute/Medical Research Council Report

(2015) Fabiana Ostronoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine in the treatment of older patients affected by acute myeloid leukemia: A report by the Rete Ematologica Pugliese (REP)

(2015) Mario Delia et al.   LEUKEMIA RESEARCH

Clinical and epidemiological characteristics of acute myeloid leukemias in adults according to the data of municipal hematology departments in Moscow

(2015) S. V. Semochkin et al.   TERAPEVTICHESKII ARKHIV

Economic analysis of blood product transfusions according to the treatment of acute myeloid leukemia in the elderly

(2015) G. Cannas et al.   TRANSFUSION CLINIQUE ET BIOLOGIQUE

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis

(2015) Jurjen Versluis et al.   Lancet Haematology

Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network

(2014) Pierre Bories et al.   AMERICAN JOURNAL OF HEMATOLOGY

Treatment of elderly patients with acute myeloid leukemia with azacitidine results in fewer hospitalization days and infective complications but similar survival compared with intensive chemotherapy

(2014) Zhentang Lao et al.   Asia-Pacific Journal of Clinical Oncology

Mobilization-Driven Postconsolidation Therapy in Elderly Patients with Acute Myeloid Leukemia: Feasibility and Efficacy of Autologous Stem Cell Transplantation versus Low-Dose Gemtuzumab Ozogamicin

(2014) Debora Capelli et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Randomized, phase 2 trial of low-dose cytarabine with or without volasertib in AML patients not suitable for induction therapy

(2014) H. Dohner et al.   BLOOD

How I treat the older patient with acute myeloid leukemia

(2014) G. Ossenkoppele et al.   BLOOD

Acute myeloid leukemia ontogeny is defined by distinct somatic mutations

(2014) R. C. Lindsley et al.   BLOOD

Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients

(2014) M. Tassara et al.   BLOOD

Role of induction and consolidation chemotherapy in elderly acute myeloid leukemia patients

(2014) Soo-Jeong Kim et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905

(2014) Thomas Prebet et al.   JOURNAL OF CLINICAL ONCOLOGY

Comorbidity and performance status in acute myeloid leukemia patients: a nation-wide population-based cohort study

(2014) L S G Østgård et al.   LEUKEMIA

Treating acute myeloid leukemia in older adults

(2014) E. S. Wang   Hematology-American Society of Hematology Education Program

Azacitidine in untreated acute myeloid leukemia: A report on 149 patients

(2013) Sylvain Thépot et al.   AMERICAN JOURNAL OF HEMATOLOGY

Guidelines International Network: Toward International Standards for Clinical Practice Guidelines

(2013) Amir Qaseem   ANNALS OF INTERNAL MEDICINE

Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia

(2013) H. D. Klepin et al.   BLOOD

Guidelines 2.0: systematic development of a comprehensive checklist for a successful guideline enterprise

(2013) H. J. Schunemann et al.   CANADIAN MEDICAL ASSOCIATION JOURNAL

Cancer Survivors in the United States: Prevalence across the Survivorship Trajectory and Implications for Care

(2013) J. S. de Moor et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients

(2013) Lieke H van der Helm et al.   Journal of Hematology & Oncology

Transfusion in Palliative Cancer Patients: A Review of the Literature

(2013) María Elena Uceda Torres et al.   JOURNAL OF PALLIATIVE MEDICINE

Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts

(2013) L.H. van der Helm et al.   LEUKEMIA RESEARCH

Geriatric assessment in older patients with acute myeloid leukemia: A retrospective study of associated treatment and outcomes

(2013) Alexander E. Sherman et al.   LEUKEMIA RESEARCH

Medicare Fee-for-Service Enrollees with Primary Acute Myeloid Leukemia: An Analysis of Treatment Patterns, Survival, and Healthcare Resource Utilization and Costs

(2013) Juliana Meyers et al.   Applied Health Economics and Health Policy

Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients

(2012) Inho Kim et al.   AMERICAN JOURNAL OF HEMATOLOGY

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia

(2012) A. Quintas-Cardama et al.   BLOOD

Survival for older patients with acute myeloid leukemia: a population-based study

(2012) B. Oran et al.   HAEMATOLOGICA

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

(2012) M. A. Sekeres et al.   HAEMATOLOGICA

Pretreatment risk factors and importance of comorbidity for overall survival, complete remission, and early death in patients with acute myeloid leukemia

(2012) Irena Djunic et al.   Hematology

Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

(2012) Hagop M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Superior Long-Term Outcome With Idarubicin Compared With High-Dose Daunorubicin in Patients With Acute Myeloid Leukemia Age 50 Years and Older

(2012) Claude Gardin et al.   JOURNAL OF CLINICAL ONCOLOGY

The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison

(2012) A K Burnett et al.   LEUKEMIA

Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia

(2012) Jay P. Patel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007

(2011) G. M. Dores et al.   BLOOD

Azacitidine for the treatment of patients with acute myeloid leukemia

(2011) Luca Maurillo et al.   CANCER

GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables

(2011) Gordon Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Low-Dose Decitabine Versus Best Supportive Care in Elderly Patients With Intermediate- or High-Risk Myelodysplastic Syndrome (MDS) Ineligible for Intensive Chemotherapy: Final Results of the Randomized Phase III Study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group

(2011) Michael Lübbert et al.   JOURNAL OF CLINICAL ONCOLOGY

Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720

(2011) M R Baer et al.   LEUKEMIA

The addition of arsenic trioxide to low-dose Ara-C in older patients with AML does not improve outcome

(2011) A K Burnett et al.   LEUKEMIA

Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience

(2010) B. C. Medeiros et al.   BLOOD

Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

(2010) B. Lowenberg et al.   BLOOD

GRADE guidelines: 2. Framing the question and deciding on important outcomes

(2010) Gordon H. Guyatt et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older

(2009) J.-L. Harousseau et al.   BLOOD

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial

(2009) Alan K. Burnett et al.   BRITISH JOURNAL OF HAEMATOLOGY

Outcomes and quality of care in acute myeloid leukemia over 40 years

(2009) Shabbir M. H. Alibhai et al.   CANCER

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

(2009) Thomas Prébet et al.   JOURNAL OF CLINICAL ONCOLOGY

Age-Specific Differences in Oncogenic Pathway Dysregulation in Patients With Acute Myeloid Leukemia

(2009) Arati V. Rao et al.   JOURNAL OF CLINICAL ONCOLOGY

Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia

(2009) Pierre Fenaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Older adults: Should the paradigm shift from standard therapy?

(2008) Elihu H. Estey   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

(2008) G. Juliusson et al.   BLOOD

Improvements in survival of adults diagnosed with acute myeloblastic leukemia in the early 21st century

(2008) D. Pulte et al.   HAEMATOLOGICA

Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia

(2008) J.-V. Malfuson et al.   HAEMATOLOGICA

Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group

(2008) Thomas Büchner et al.   JOURNAL OF CLINICAL ONCOLOGY

Acute Myeloid Leukemia in the Elderly

(2008) Hervé Dombret et al.   SEMINARS IN ONCOLOGY

GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

(2008) Gordon H Guyatt et al.   BMJ-British Medical Journal